---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-144174"
form_type: "8-K"
ticker: "FBRX"
cik: "0001419041"
company_name: "Forte Biosciences, Inc."
filed_at: "2025-06-23T23:59:59+00:00"
generated_at: "2026-05-18T23:30:43.139590+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Forte Biosciences reports positive Phase 1b data for FB102 in celiac disease; Phase 2 initiating

## Summary
- Composite histological VCIEL endpoint met: FB102 mean change 0.079 vs placebo -1.849 (p=0.0099).
- CD3+ IELs declined by 1.5 on FB102 vs increase of 13.3 for placebo (p=0.0035).
- Gluten challenge GI symptom events per subject: 4.0 for FB102 vs 6.9 for placebo (42% benefit).
- No grade 3+ SAEs in FB102 arm; all TEAEs mild; no dropouts.
- Phase 2 celiac trial initiating; topline readout expected in 2026; vitiligo readout H1 2026.

## SEC filing metadata
- accession: 0001193125-25-144174
- form_type: 8-K
- ticker: FBRX
- cik: 0001419041
- company_name: Forte Biosciences, Inc.
- filed_at: 2025-06-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1419041/000119312525144174/0001193125-25-144174-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1419041/000119312525144174/d874957d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-144174
- JSON: https://secwatch.observer/filing/0001193125-25-144174.json
- Plain text: https://secwatch.observer/filing/0001193125-25-144174.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.